Last reviewed · How we verify
Lymphodepletion Chemotherapy
At a glance
| Generic name | Lymphodepletion Chemotherapy |
|---|---|
| Also known as | Fludarabine, Cyclophosphamide |
| Sponsor | Marcela V. Maus, M.D.,Ph.D. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
- Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (PHASE1)
- Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia (PHASE1)
- Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. (PHASE1)
- Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma (EARLY_PHASE1)
- Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors (EARLY_PHASE1)
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lymphodepletion Chemotherapy CI brief — competitive landscape report
- Lymphodepletion Chemotherapy updates RSS · CI watch RSS
- Marcela V. Maus, M.D.,Ph.D. portfolio CI